The pursuit of outperformance leads many investors to carefully choose individual stocks. Picking the right ones can be a game-changer for growing your wealth.
As of close of business last night, Syndax Pharmaceuticals Inc’s stock clocked out at $13.13, down -2.31% from its previous closing price of $13.44. In other words, the price has decreased by -$2.31 from its previous closing price. On the day, 1.16 million shares were traded. SNDX stock price reached its highest trading level at $13.455 during the session, while it also had its lowest trading level at $12.7.
Ratios:
To gain a deeper understanding of SNDX’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 5.82 and its Current Ratio is at 5.82. In the meantime, Its Debt-to-Equity ratio is 1.20 whereas as Long-Term Debt/Eq ratio is at 1.16.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, UBS on October 24, 2024, initiated with a Buy rating and assigned the stock a target price of $37.
On June 28, 2024, Jefferies started tracking the stock assigning a Buy rating and target price of $37.
Scotiabank Downgraded its Sector Outperform to Sector Perform on January 31, 2024, whereas the target price for the stock was revised from $36 to $23.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Mar 04 ’25 when Metzger Michael A sold 7,814 shares for $15.05 per share. The transaction valued at 117,564 led to the insider holds 300,121 shares of the business.
MICHAEL METZGER bought 13,888 shares of SNDX for $214,986 on Mar 04 ’25. On Feb 10 ’25, another insider, Goldan Keith A., who serves as the Chief Financial Officer of the company, sold 3,777 shares for $15.50 each. As a result, the insider received 58,559 and left with 90,746 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, SNDX now has a Market Capitalization of 1156167424 and an Enterprise Value of 892326272. For the stock, the TTM Price-to-Sale (P/S) ratio is 47.70 while its Price-to-Book (P/B) ratio in mrq is 3.91. Its current Enterprise Value per Revenue stands at 37.683 whereas that against EBITDA is -2.627.
Stock Price History:
The Beta on a monthly basis for SNDX is 1.24, which has changed by -0.41742522 over the last 52 weeks, in comparison to a change of 0.10063088 over the same period for the S&P500. Over the past 52 weeks, SNDX has reached a high of $25.07, while it has fallen to a 52-week low of $12.06. The 50-Day Moving Average of the stock is -7.74%, while the 200-Day Moving Average is calculated to be -25.46%.
Shares Statistics:
It appears that SNDX traded 2.18M shares on average per day over the past three months and 1406410 shares per day over the past ten days. A total of 85.69M shares are outstanding, with a floating share count of 84.15M. Insiders hold about 2.18% of the company’s shares, while institutions hold 111.94% stake in the company. Shares short for SNDX as of 1741910400 were 18823847 with a Short Ratio of 8.62, compared to 1739491200 on 21551361. Therefore, it implies a Short% of Shares Outstanding of 18823847 and a Short% of Float of 22.06.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
